<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136760</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-17566-1</org_study_id>
    <secondary_id>R01DA017566</secondary_id>
    <secondary_id>R01-17566-1</secondary_id>
    <nct_id>NCT00136760</nct_id>
  </id_info>
  <brief_title>Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia</brief_title>
  <official_title>Incentives Plus Bupropion for Smoking in Schizophrenics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a high prevalence of smoking among people with schizophrenia, and there are few
      smoking treatment programs for these smokers. The aims of this study are to investigate the
      separate and combined effects of bupropion and a voucher incentive program on smoking in
      people with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a high prevalence of smoking among people with schizophrenia, and there are few
      smoking treatment programs for these smokers. In this study, we are investigating whether the
      combination of bupropion (also called Zyban and Wellbutrin) and a behavioral treatment
      program (contingent vouchers) can reduce smoking in people with schizophrenia. This is a
      3-week study aimed to investigate the feasibility of this treatment approach. Participants
      are randomly assigned to bupropion (300 mg/day, in 2 divided doses) or placebo. After one
      week on medication, participants are randomly assigned to the active behavioral treatment
      (contingent vouchers) or the control treatment (non-contingent vouchers). Over a 3-week
      period, participants come to the study site about 2-3 times per week, and provide information
      about their recent smoking and nicotine withdrawal symptoms. They also give saliva and urine
      samples that are analyzed for levels of cotinine, a nicotine metabolite. Participants in the
      active behavioral treatment group receive gift cards to local grocery stores when their
      cotinine levels indicate that they have reduced their smoking. Participants in the control
      behavioral treatment group receive gift cards regardless of cotinine level. Any participant
      who significantly reduces their smoking at the end of the trial is followed up 2 and 4 weeks
      after the end of the trial too see if they have sustained these smoking reductions. If we
      have favorable results from this trial, we will expand it into a smoking treatment program.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Cotinine</measure>
    <time_frame>3 weeks</time_frame>
    <description>Urinary Cotinine levels at Week 4 (average of last 3 study visits)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cigarettes Smoked Per Day</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Schizophrenia and Disorders With Psychotic Features</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contingent reinforcement plus bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contingent reinforcement plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-contingent reinforcement plus bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-contingent reinforcement plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>zyban, wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Contingent reinforcement plus placebo</intervention_name>
    <description>contingent reinforcement plus placebo (3 weeks)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-contingent reinforcement plus bupropion</intervention_name>
    <description>non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)</description>
    <arm_group_label>3</arm_group_label>
    <other_name>zyban, wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-contingent reinforcement plus placebo</intervention_name>
    <description>Non-contingent reinforcement plus placebo</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of schizophrenia or schizoaffective disorder, smoke 20-50 cpd, clinically stable
        on antipsychotic and antidepressant medications

        Exclusion Criteria:

        Pregnant/nursing women, seizure disorder, lowered seizure threshold due to other medical
        conditions, positive urine drug screen positive breath alcohol test, past 2 weeks use of
        MAO inhibitors, any form of bupropion, cimetidine, phenobarbital, phenytoin, DA agonists,
        anorectics, stimulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer W. Tidey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology (Berl). 2011 Sep;217(2):279-87. doi: 10.1007/s00213-011-2282-8. Epub 2011 Apr 8.</citation>
    <PMID>21475970</PMID>
  </results_reference>
  <results_reference>
    <citation>Tidey JW. Using incentives to reduce substance use and other health risk behaviors among people with serious mental illness. Prev Med. 2012 Nov;55 Suppl:S54-60. doi: 10.1016/j.ypmed.2011.11.010. Epub 2011 Dec 9. Review.</citation>
    <PMID>22197799</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <results_first_submitted>November 16, 2012</results_first_submitted>
  <results_first_submitted_qc>November 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2012</results_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Jennifer Tidey</investigator_full_name>
    <investigator_title>Associate Professor (Research), Dept Psychiatry and Human Behavior</investigator_title>
  </responsible_party>
  <keyword>tobacco</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Schizophrenia Spectrum and Other Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the community, using advertisements, and were recruited from an outpatient clinic at a local VA medical Center.</recruitment_details>
      <pre_assignment_details>Participants underwent telephone and in-person screening for eligibility criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CM + BUP</title>
          <description>Contingent reinforcement plus bupropion</description>
        </group>
        <group group_id="P2">
          <title>CM + PLA</title>
          <description>Contingent reinforcement plus placebo</description>
        </group>
        <group group_id="P3">
          <title>NR + BUP</title>
          <description>Non-contingent reinforcement plus bupropion</description>
        </group>
        <group group_id="P4">
          <title>NR + PLA</title>
          <description>Non-contingent reinforcement plus placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CM + BUP</title>
          <description>Contingent reinforcement plus bupropion</description>
        </group>
        <group group_id="B2">
          <title>CM + PLA</title>
          <description>Contingent reinforcement plus placebo</description>
        </group>
        <group group_id="B3">
          <title>NR + BUP</title>
          <description>Non-contingent reinforcement plus bupropion</description>
        </group>
        <group group_id="B4">
          <title>NR + PLA</title>
          <description>Non-contingent reinforcement plus placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="11.9"/>
                    <measurement group_id="B2" value="46.3" spread="6.7"/>
                    <measurement group_id="B3" value="43.7" spread="7.3"/>
                    <measurement group_id="B4" value="46.9" spread="6.8"/>
                    <measurement group_id="B5" value="45.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Cotinine</title>
        <description>Urinary Cotinine levels at Week 4 (average of last 3 study visits)</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CM + BUP</title>
            <description>Contingent reinforcement plus bupropion</description>
          </group>
          <group group_id="O2">
            <title>CM + PLA</title>
            <description>Contingent reinforcement plus placebo</description>
          </group>
          <group group_id="O3">
            <title>NR + BUP</title>
            <description>Non-contingent reinforcement plus bupropion</description>
          </group>
          <group group_id="O4">
            <title>NR + PLA</title>
            <description>Non-contingent reinforcement plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Cotinine</title>
          <description>Urinary Cotinine levels at Week 4 (average of last 3 study visits)</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="755" spread="533"/>
                    <measurement group_id="O2" value="1102" spread="639"/>
                    <measurement group_id="O3" value="1534" spread="489"/>
                    <measurement group_id="O4" value="1408" spread="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cigarettes Smoked Per Day</title>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CM + BUP</title>
            <description>Contingent reinforcement plus bupropion</description>
          </group>
          <group group_id="O2">
            <title>CM + PLA</title>
            <description>Contingent reinforcement plus placebo</description>
          </group>
          <group group_id="O3">
            <title>NR + BUP</title>
            <description>Non-contingent reinforcement plus bupropion</description>
          </group>
          <group group_id="O4">
            <title>NR + PLA</title>
            <description>Non-contingent reinforcement plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cigarettes Smoked Per Day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="7.4"/>
                    <measurement group_id="O2" value="13.9" spread="9.5"/>
                    <measurement group_id="O3" value="18.8" spread="12.9"/>
                    <measurement group_id="O4" value="21.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CM + BUP</title>
          <description>Contingent reinforcement plus bupropion</description>
        </group>
        <group group_id="E2">
          <title>CM + PLA</title>
          <description>Contingent reinforcement plus placebo</description>
        </group>
        <group group_id="E3">
          <title>NR + BUP</title>
          <description>Non-contingent reinforcement plus bupropion</description>
        </group>
        <group group_id="E4">
          <title>NR + PLA</title>
          <description>Non-contingent reinforcement plus placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <description>self-report</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea, vomiting</sub_title>
                <description>self-report</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>bleeding ulcer</sub_title>
                <description>self-report, not related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>opiate detoxification</sub_title>
                <description>self-report</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>anxiety, restlessness</sub_title>
                <description>self-report, not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>blackout</sub_title>
                <description>self-report, not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Tidey, Ph.D.</name_or_title>
      <organization>Brown University</organization>
      <phone>401-863-6418</phone>
      <email>Jennifer_Tidey@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

